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Abstract: 
 
High rates of antibiotic use have resulted in the pervasiveness of multi-drug resistant 
organisms. With rising drug-resistance the development of antibiotics with new targets against 
these pathogens is imperative. The T-box regulatory mechanism is a process specific to Gram-
positive bacteria and controls many essential genes including aaRS genes, which are code for the 
aminoacyl-tRNA synthetases required to charge tRNA. The T-box Specifier Loop is a novel 
target for antibacterial drug discovery as we hypothesize that a small compound bound to the 
Specifier Loop will inhibit transcription of essential bacterial genes resulting in bacterial cell 
death or growth arrest. We used an in silico drug discovery approach combined with structure-
activity relationship studies (SAR) to evaluate small molecules as potential putative antibiotics 
directed against Gram-positive bacteria. SAR studies have been used to determine important 
structural elements of the initial hit compounds so that a compound with optimal activity and 
Gram-positive selectivity can be developed into an antimicrobial agent.  
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Introduction: 
Many drug-resistant pathogens have risen in frequency and lethality. High rates of 
antibiotic use have resulted in the pervasiveness of advantageous mutations against antibiotics.
1
 
This epidemic of resistance has developed from increased frequency of prescription, which is 
supported by studies showing a positive correlation between the amounts of regional antibiotic 
consumption with the rate of prevalence of antibiotic resistant bacterial infections. The US 
Centers for Disease Control and Prevention conservatively approximate 2 million illnesses and 
23,000 deaths annually as a consequence of resistance (Zhang et al)
2 
An increase in resistance of 
bacterial infections in healthcare facilities is beginning to reduce the amount of available 
antimicrobial agents. Thus, the development of antibiotics with new targets against multi-drug 
resistant organisms is imperative. Addressing the issue of resistance has brought a focus onto 
nosocomial infections that are developing strong resistance to current antibiotic treatments. 
1
 
 
Gram-positive bacterial infections have demonstrated increasing resistance despite many 
attempts to preclude the evolution of these microorganisms. Gram-positive cocci bacteria 
specifically demonstrate dangers as strains such as, Methicillin Resistant Staphylococcus aureus 
(MRSA), Penicillin Resistant Streptococcus pneumoniae (PRSP), Vancomycin Resistant 
Enterococci (VRE), and many others have broadened resistance to many of their current 
treatments. A surveillance study, conducted on nosocomial infections and their transmission 
throughout 463 hospitals in China, demonstrated that the prevalence of MRSA was much higher 
in ICU patients (77.6%) than in both inpatients (50.2%) and out patients (26.1%). Evaluation of 
the prevalence of resistant strains conducted during 2006-2007 demonstrated that across the 463 
hospitals all had at least 1 hospital associated infection (HAI). Further data showed that 28,502 
HAIs were reported across 25,384 patients, which reflects the frequency of nosocomial 
infections. On the basis of this study, the 10 most common HAIs were determined in these 
hospitals and the 3 most prevalent of these infections were Gram-positive organisms.
3
  
The excessive use of antibiotics in a variety of circumstances, which may be deemed 
inappropriate or unnecessary, have resulted in the acceleration of resistance. Estimates 
approximate that about 50% of prescribed antibiotics are inappropriate. The development of new 
antibiotics with decreased opportunity for resistance is integral as research must be cost effective 
in searching for new antimicrobial treatments.
4
 There have only been three new classes of 
antibiotics that have been introduced since the year 2000. Thus, the need for non-toxic antibiotics 
against multi-drug resistant Gram-positive organisms is crucial.
5 
Comprehension of current 
antibiotic mechanisms is an essential aspect of understanding the development of resistance and 
how to find future antibacterial agents to combat these evolving organisms. There are 5 major 
target mechanisms of which current antimicrobials interfere or inhibit, including (1) cell wall 
synthesis; (2) protein synthesis; (3) nucleic acid synthesis; (4) a metabolic pathway; or (5) the 
bacterial membrane structure.
4
 
Evolutionary adaptations have allowed bacterial infections to evolve several mechanisms 
of resistance. Intrinsic resistance is the use of a natural mechanism that is innate to a bacterium. 
Acquired resistance, on the other hand, is the development of spontaneous mutations or 
acquisition of genes through methods such as horizontal gene transfer. Four major mechanisms 
of resistance have arisen including alteration of antibiotic binding site, creation of enzymes that 
inactivate or destroy the antibiotic, development of an efflux pump, and development of a porin 
or channel that prevents entry of an antibiotic into the cell.
4
  
There are many modifications that can occur in the binding site of the antibiotic and can 
prevent it from acting on its target.
4
 This mechanism is one of the ways Gram-positive organisms 
have evolved against Beta Lactams, which are some of the oldest currently used antibiotics. This 
class of antibiotics includes many molecules, all of which contain a B-Lactam ring, including 
Penicillins, Cephalosporins, and Monobactams. The mechanism of action for these antibiotics is 
to interfere with enzymes such as transpeptidases, carboxypeptidases, and endopeptidases, which 
are necessary for the building and maintaining peptidoglycan of the cell wall. These enzymes are 
often referred to as Penicillin Binding Proteins (PBPs). Many Gram-positive organisms have 
developed resistance that interferes with these antibiotics binding site. S. pneumoniae became 
resistant to Penicillins and Cephalosporins as a result of a mutation in the PBP gene, causing the 
antibiotic target site to be modified. These modifications rendered these drugs ineffective 
because the organism developed PBPs that no longer could bind the Beta Lactam ring. Both S. 
aureus and Enterococcus faecium developed resistance to antibiotics in the Beta Lactam class 
via target site modification. The development of this type of resistance is dangerous, as they are 
genetically transferrable across species allowing other bacterial strains to create mutant PBPs. 
6
  
 Another extremely common method of resistance is the evolution of enzymes that have 
developed the capability to inactivate drugs. This method of resistance has caused great 
devastation to current treatments.
4
 The Gram-positive bacteria Mycobacterium tuberculosis has 
developed resistance to the aminoglycoside (AG), Kanamycin A (KAN), which targets the 30s 
ribosomal subunit. M. tuberculosis was able to adapt through the development of mutations on 
the promotor region of the eis (enhanced intracellular survival) gene resulting in a gain of 
function of AG acetyltransferases, which acetylates the antibiotic destroying its activity. In this 
case, M. tuberculosis developed AG acetyltransferases that are capable of acetylating the amino 
group of KAN causing inactivation. This gene has been seen in other organisms and can pose a 
great danger to the ability to treat this multi-drug resistant Gram-positive pathogen that has 
shown incredible resilience.
7 
Resistance such as this has occurred in Gram-positive organisms 
against other antibiotics such as, Beta Lactams, which are hydrolyzed on the beta lactam ring by 
Beta Lactamases resulting in inactivity.
4
 
The development of efflux pumps is an example of intrinsic resistance that can 
potentially eradicate currently used antibiotics. Some estimates predict that 5-10% of bacterial 
genes contribute to this function.
8
 In many cases, if this mechanism develops against a non-
specific antibiotic, then it will likely prevent the effectivity of the other antibiotics with a similar 
mode of action, making this mechanism highly dangerous. Gram-positive pathogens utilize this 
resistance mechanism for a variety of antimicrobial agents. Organisms have developed efflux 
mechanisms against several antibiotics from the fluoroquinolone class including ciprofloxacin, 
norfloxacin, and ofloxacin. These antibiotics target DNA synthesis machinery, including DNA 
gyrase and topoisomerase.
4 
Efflux pumps are more precarious than other methods of resistance, 
in that they may be a bridge as a single step mutant can result in a multi-drug resistant pathogen.  
This occurs when low level resistance created by efflux pumps to one antibiotic in the class 
eventually results in resistance to several antibiotics within the class.
8 
The final mechanism is the altering of porin channels that prevent drug entry, which 
lowers the antibiotic concentration in the cell. This mechanism is more common in Gram-
negative organisms because they have an additional outer membrane that consists of a lipid 
bilayer.
4 
Porins are open pores in the membrane and antibiotics are able to pass through these 
pores to gain easy access into the cell. This is especially effective as many of the antibiotics that 
are currently used have intracellular targets. Bacterial cells can develop resistance to this through 
alteration to the voltage and conductance of these porins putting them into a closed or inactivated 
state that will not allow entry of the antibiotic into the cell. This mechanism is utilized by many 
Gram-negative pathogens such as, Pseudomonas aeroginos, Neisseria gonorrhoeae, 
Enterobacter aerogenes, klebsiella pneumonia and many others.
9
 However, this can occur in 
Gram-positive pathogens, such as Vancomycin-intermediate S. aureus (VISA), which displays 
phenotypic passage-selection against the antibiotic Vancomycin resulting from the development 
a thickened peptidoglycan wall to prevent Vancomycin access into the cell.
10
 
With resistance on the rise and Gram-positive infections utilizing many mechanisms to 
combat all current treatments, there is a desperate need for the development of new antibiotics. 
In 2013, Gram-positive organisms appeared in all three categories of CDC’s levels of concern 
including Urgent Threats, Serious Threats, and Concerning Threats. The economic effects of 
these infections have been devastating due to the expense of hospitalization and loss of work 
force. Approximations for the year 2008 are 20 billion dollars in healthcare expenses exacerbated 
by an additional estimated cost of 35 billion dollars from loss of work productivity.
11
 
Currently, the most dangerous Gram-positive organism is Clostridium difficile, which has 
had catastrophic effects on American society causing 250,000 infections and 14,000 deaths per 
year. This organism was classified as an Urgent Hazard Level due to its potential to become 
widespread across the country. C. difficile occurs on a nosocomial and non-nosocomial basis 
costing 1 billion dollars in excess medical costs per year. This microorganism has had a drastic 
impact on the senior citizen population; killing 90% of the senior citizens that it infects. Other 
dangers include, Drug-Resistant S. pneumoniae, which is currently considered at Serious Threat 
Level and causes 1.2 million infections annually, 7000 deaths, and costs 19,000 dollars in excess 
hospitalizations. Approximately, 160,000 children under the age of 5 will be admitted into a 
hospital as a result of this Gram-positive infection. Several other resistant organisms have also 
bombarded the healthcare system. S. aureus has expanded its resistance against many of the past 
successful antibiotics. With new strains evolving against current antibiotics, including methicillin 
resistant S. aureus (MRSA) and Vancomycin-resistant S. aureus (VRSA), which are Serious 
Threat and Concerning Threat levels respectively. It is essential that new antibiotic targets are 
discovered against Gram-positive bacteria.
11,12
  
All of these infections are evolving resistance via aforementioned mechanisms and 
resulting in drastic health care costs, morbidity and mortality. The resistance rate has drastically 
increased as treatments of patients in chemotherapy, complex surgery, afflicted with rheumatoid 
arthritis, dialysis for renal disease or receiving organ and bone marrow transplants all pose high 
risk for infections. The use of antibiotics in these patients breeds resistance because of decreased 
ability to fight infection as a result of immunodeficiency. In many cases certain antibiotics 
cannot be used or are dose limited because of the toxicity in patients with some of these 
conditions, posing a great threat for the development of resistance. This is due to the fact that 
low doses expose many bacteria to the antibiotic, but may not effectively kill every viable cell. 
This may result in spontaneous mutations that create resistance to an antibiotic. Ultimately, even 
limiting the over-prescription of antibiotics, preventing infection, and tracking infections will 
only slow and not eliminate the problem of resistance.
11
 
 
RNA has increasingly become recognized as an advantageous target for antibiotic drug 
development in the fight against antibiotic resistance. The integral nature of RNA in the genetic 
and functional processes of a cell makes it a desirable target for drugs. Riboswitches are RNA 
regulatory elements that change structural conformation upon metabolite or ligand binding to 
alter gene expression. These metabolite sensing regulators are energetically conservative as they 
almost exclusively occur at the 5’UTR preventing unnecessary transcription of the operon. The 
region with the most conservation is the four nucleotide binding domain that is often referred to 
as the “aptamer” domain. Interaction at this aptamer domain results in a second binding event at 
the “expression platform”, which determines whether or not downstream gene expression will 
occur.
13
 
The T-box regulatory mechanism is not a riboswitch in a conventional sense, but it 
functions very similarly in its method of regulation. This regulatory element’s is specific to 
Gram positive bacteria and is used by many operons encoding essential genes. One essential 
gene that is regulated through this mechanism is the aaRS gene, which is responsible for making 
aminoacyl-tRNA synthetases. These enzymes are essential for catalyzing reactions that charge 
the tRNA with the proper amino acids.
 14 
Regulating at the transcription attenuation level, the T-
box mechanism efficiently uses the binding of a charged and uncharged tRNA species to regulate 
translation of amino-acid related genes, such as amino-tRNA synthetases and amino acid 
transporters. The tRNA species anticodon specificity is essential to regulation as deviation in a 
single nucleotide can result in a significant decrease in expression of genes.
15
  
T-box regulation consists of a specific tRNA binding to two distinct regions in the 5’ 
UTR. Figure 1 illustrates these binding events and the formation of both the attenuation and 
downstream reading events.
 
The first interaction occurs in stem I at the Specifier Loop where a 
base pair binding event between the anticodon of a specific tRNA and the Specifier Loop on 
Stem I of the 5’UTR occurs. After the first binding event, a second binding event will occur at 
the second Loop taking the form of one of two potential structures, a terminator or antiterminator 
helix. If the binding tRNA is charged, the amino acid present prevents stabilization of the 
antiterminator helix and a terminator Loop is formed, resulting in no downstream reading of the 
operon. The T-box mechanism is predisposed to termination as the terminator helix is a more 
thermodynamically stable structure then the anti-terminator helix. However, if an uncharged 
tRNA is bound to the Stem I Specifier Loop, then the interaction will promote a second binding 
event between the NCCA sequence at the acceptor end of the tRNA and the UGGN residues of 
anti-terminator bulge region in Stem II of the mRNA 5’UTR. This interaction prevents the 
formation of the terminator helix allowing for expression of the downstream coding sequences.
15
 
Specific tRNA recognition by the nascent transcript will result in an increased expression of the 
genes imperative to tRNA aminoacylation.
14
  
Figure 1 
 
 
 
 
 
 
 
 
 
Figure 1: 
“The T box mechanism. Expression of genes in the T box family is regulated by the ratio 
of charged to uncharged tRNA in the cell. (A) Aminoacylated tRNA binds only to the 
Specifier Loop; the presence of the amino acid prevents interaction of the acceptor end of 
the tRNA with the antiterminator. The more stable terminator helix (blue-black) forms 
and transcription terminates. (B) Uncharged tRNA interacts at both the Specifier Loop 
and the antiterminator; this stabilizes the antiterminator (red-blue) which sequesters 
sequences (blue) that otherwise participate in formation of the terminator helix, and 
transcription reads through the termination site and into the downstream coding sequence. 
Binding of uncharged tRNA results in structural changes throughout the leader RNA. The 
tRNA is shown in cyan; the amino acid (aa) is shown as a yellow circle attached to the 3′ 
end of the charged tRNA. Positions of base-pairing between the leader RNA and the 
tRNA (Specifier Loop–tRNA anticodon, antiterminator bulge–tRNA acceptor end) are 
shown as green lines.” 
Description and Image Adapted from:  
Nicholas J.  Green , Frank J.  Grundy , Tina M.  Henkin 
“The T box mechanism: tRNA as a regulatory molecule” 
FEBS Letters, Volume 584, Issue 2, 2010, 318 – 324 
http://dx.doi.org/10.1016/j.febslet.2009.11.056 
As aforementioned, this process requires Specifier sequence recognition of the tRNA 
anticodon and the anti-terminator bulge that interacts with the acceptor end of the tRNA. The 
tRNA recognition site has an apex region with an adenosine-guanine bulge that is referred to as 
the distal Loop. The Loop to Loop structural region serves as a docking platform for the tRNA to 
bind for gene expression. This marks some of the major similarities to the structural events that 
occur in a conventional riboswitch.
14
 Further evidence to support the riboswitch nature of this 
mechanism is that in vivo and in vitro studies demonstrate that a single tRNA in its entirety is 
sufficient to promote the regulatory response.
16 
The genes encoded by the T-box mechanism are essential genes for bacterial growth and 
proliferation. Multiple T-boxes are present in a single organism. Many Gram-positive bacteria 
such as, Bacillus Subtilis and S. pneumoniae, which have been shown to contain T-boxes 
upstream of valS, pheS, pheT, glyQ, glyS, thrS, and ileS genes as well as for other genes as 
well.
17
 The T-box Specifier Loop is a novel target for antibacterial drug discovery as we 
hypothesize that a small compound bound to the Specifier Loop will inhibit transcription of 
essential bacterial genes resulting in bacterial cell death or growth arrest. Due to the conserved 
nature of the Specifier Loop there is potential for a broad spectrum of antibacterial activity 
against Gram-positive pathogens. Since there are multiple T-boxes within each bacterium, there 
is a decreased chance of resistance emerging, as a single small molecule antibiotic could shut off 
multiple T-boxes limiting the bacteria’s ability to evolve by altering the antibiotics binding site. 
The high conservation of this region suggests that any major alteration to this binding site may 
result in a loss of function and bacterial cell death. The T-box regulatory mechanism is not 
present in eukaryotic cells, which reduces the potential for cytotoxicity. With these factors in 
mind, a small molecule that can bind to T-boxes and disrupt gene regulation is a strong candidate 
for development of new antibiotics.
16
  
Using in silico analysis of the T-box Specifier Loop, small compounds that are likely to 
disrupt T-box function were identified. Bacterial growth arrest studies identified three initial hit 
compounds, one of which demonstrated Gram-positive specificity and displayed moderate-to-
low cytotoxicity in human cells. Based on this data, structure activity relationship studies (SAR) 
were conducted with disk diffusion assays against S. aureus with structural analogs of our initial 
hits. Minimum Inhibitory Concentration (MIC) assays and Minimum Bactericidal Concentration 
(MBC) assays were conducted against S. aureus and the Gram-negative bacterium Escherichia 
coli for analogs that displayed antibacterial activity with disc diffusion assays. Using the 
successful compound structures as a template, an additional in silico docking study was 
conducted on selected analogs with structures identified as essential to antibiotic activity. Top 
candidates of this docking simulation as well as other carefully selected analogs will be tested 
using both MIC and MBC assays to further assess and refine structural determinants required for 
antibacterial activity. These SAR studies have allowed for the determination of important 
biochemical features for Gram-positive activity including, the heterocyclic thiazole, norbornane 
carboxylic acid, and benzene. Evidence suggests that a meta orientation on the benzene ring 
between the thiazole and a long carbon chain may produce optimal antimicrobial activity.  
Methods: 
Chemical Compound Re-suspension:  
Compounds were commercially available and purchased from Ambinter, Asinex, 
Enamine, Akos, Molport, Prinston Biomoleular and Chembridge.  All compounds that were used 
for the experiments were suspended in 100% DMSO at a concentration of 15 mg/mL for disk 
diffusion assays and 10mg/mL for MIC assays. DMSO was chosen because many of the 
compounds displayed poor solubility in the presence of standard media or water. All compounds 
were aliquoted and stored at -80°C until the day of the experiment.  Individual aliquots of 
compound, gentamicin and DMSO were thawed on ice on the day of an experiment. Control 
antibiotics were prepared in 100% H2O, and stored at -20°C until experimental use. 
Bacterial Culturing: 
Staphylococcus aureus, subsp. aureus Rosenbach ATCC 29213 (ATCC) was used for all 
anti-microbial activity experiments. This strain was used as it is laboratory strain of S. aureus 
commonly used for anti-microbial activity testing.  For each experiment, different types of 
media’s were used, Tryptic Soy Broth (TSB) and Luria Bertani agar (LBA). The TSB (Sigma) 
was used for growth of liquid cultures and prepared water as per manufacturer’s instructions, and 
supplemented with 2.5 g of dextrose per liter of media as a preferred carbon source. Media was 
sterilized by autoclave. An overnight culture was set up prior to each experiment by placing a 3-
4 morphologically similar colonies of S. aureus into a sterile culture tube with 3 mL of TSB. The 
culture was placed in a shaking incubator at 37 °C for 18 hours at 225 rpm. After 18 hours a new 
culture was prepared so that the bacteria would be in the logarithmic stage of growth for each 
experiment. Using the overnight culture, 60 µL of bacterial culture was pipetted into a new tube 
of 2.94 mL of TSB. This culture provided a 1:50 ratio of bacteria to media and was placed in the 
shaking incubator at 37°C for 3-4 hours prior to the experiment so that bacterial culture would be 
in logarithmic stage of growth. An OD600 reading between 0.4-0.8 indicates exponential growth 
stage. LB agar was chosen as solid media for antibiotic susceptibility testing. The media was 
made with a ratio 35 g of media per liter of DI water as per manufactures instructions. Media 
was sterilized by autoclave and poured into sterile petri dishes with a volume of 25 mL in each 
plastic petri dish to ensure reproducibility. All media was made and poured under sterile 
conditions to prevent contamination. Plates were stored at 4°C. 
Disk Diffusion Assay:  
The antimicrobial susceptibility testing was done using the Kirby-Bauer disc diffusion 
method. Disk diffusion assay protocol was modeled after Bauer et al.
18
 Under sterile conditions 
disks were placed on a prepared sterile sheet of aluminum foil and compounds were spotted onto 
each disk at a concentration of 150 µg/mL. A sterile cotton swab was dipped into the bacterial 
solution of S. aureus and then used to completely cover the surface of a pre-warmed LB agar 
plates. Plates were dried in an incubator for 10 minutes and then the spotted disks were placed 
onto the inoculated petri dishes antibiotic side down to maximize compound diffusion through 
the agar. Following incubation for 18 hours at 37 °C, the zones of inhibition were measured and 
photographed. After all compounds were tested in triplicate, those with ambiguous results were 
retested in triplicate at a higher concentration of 300 µg/mL using the same procedure stated 
above. This was done so that all compounds that successfully inhibited bacterially growth could 
be determined accurately.  
 
Minimum Inhibitory Concentration (MIC)/Minimum Bactericidal Assays (MBC): 
The minimum inhibitory concentration assay is used to determine the lowest 
concentration that an antimicrobial can inhibit visible growth of bacteria. The results of the MIC 
assay can be used to conduct a minimum bactericidal assay, which is used to determine the 
lowest effective concentration that an antimicrobial kills all viable bacteria. Prior to the 
experiment all The MIC assay was set up using a 96 well plate. All MICs and MBC 
antimicrobial testing was conducted based on the NCCLS standard with modifications.
19
 
Compounds were serially diluted 2-fold from 481 µg/mL to 0.23 µg/mL.  There was a sterility 
control well containing 100 μL TSB where no inoculum was added. A growth control well was 
implemented with 80μL TSB to which 20 μL standardized inoculum was added.  A DMSO 
control was used to ascertain the growth level in the presence of solvent without compound, 
which was used to demonstrate any impact of the presence of the final 4.81% DMSO. 
Additionally, Gentamicin, a clinical antibiotic, was used as a control and was serially diluted two 
fold from 48.1 µg/mL to 0.092 µg/mL to confirm expected MIC against laboratory strain of use. 
A culture in exponential growth was diluted as per the McFarland Standard to OD600 of 0.08 to 
0.12 which contains 1-2x10
8
 CFU/mL. After an additional 1:2.5 dilution was carried out. All 
wells were inoculated within 15 minutes of dilution with 20 µL containing 8x10
5 
CFU/mL.  
After all necessary wells were inoculated and thoroughly mixed, a micro plate reader was used to 
measure the OD600 of each well. The plate was then allowed to shake at 100 rpm at 37°C in the 
incubator for 20 hours. After this time period, another OD600 reading was taken to determine a 
change in optic density. This provided a quantitative determination to whether or not there is 
bacterial growth. The MIC was determined as the lowest compound concentration at which no 
visible growth was observed. Criteria for MIC was assessed using graphed data assigning a MIC 
value based on the concentration that showed close to a 100% inhibition just prior to a large 
increase in growth. 
To determine the MBC, all wells from the MIC experiment with a concentration equal or 
greater than the MIC were individually spread onto separate dishes of LB agar and incubated at 
37°C for 24 hours. The MBC was recorded as the lowest compound concentration where there 
were no viable bacterial colonies. If the MBC was is no more then 4 fold of the MIC of a specific 
compound then this compound was determined to be bactericidal and if it was not then it was 
deemed bacteriostatic. 
In silico screening:  
 Using in silico analysis, 250,000 small molecules were screened to determine 
compounds likely to bind to the T-box Specifier Loop of the Gram-positive bacterium, Bacillus 
subtilis. Of this large small molecule database, 200 molecules showed potential to disrupt T-box 
function. This work was conducted by Albany Molecular Research Institute using sophisticated 
computer technology that assessed the binding energy of small molecules to the target. From this 
list of 200 compounds, 28 of these were selected for bacterial growth arrest studies. Figure 2 
demonstrates the progression of compounds from the initial in silico to the analogs currently 
being tested. Biological testing resulted in the identification of two initial hit compounds PKZ 
1800, and PKZ 0600, which became the focus for structure-activity relationship studies based on 
their greater antimicrobial activity and Gram-positive selectivity. To narrow necessary structural 
elements for antimicrobial activity, we began SAR studies of analogs of these two initial hit 
compounds. SAR round 1 was conducted with disk diffusion assays against S. aureus using 20 
structural analogs of parent compound PKZ 1800 and 15 analogs of PKZ 0600. An additional 15 
compounds were tested from the original list of 200 in search of more effective small molecule 
families then current initial hits under SAR evaluation. 
Based on the data provided by both the disk diffusion and liquid screening assays, 
structural searches were conducted in small molecule libraries that are publicly available. These 
searches were based on modifications to parent compound PKZ 1800 in a chemical draw 
program so that analogs with specific desired structures could be found. An additional in silico 
analysis was done by The RNA Institute of 22 compounds chosen from these chemical libraries. 
This additional in silico was conducted to determine binding energies of these new potential 
compounds for future testing in search of a PKZ 1800 analog that may have improved biological 
activity. Binding energies of each compound for the second in silico were ascertained and 
compared to prior successful parent compound PKZ 1800 as well as ethanol as a negative 
control. 
Figure 2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
This figure demonstrates the chronological of compound testing and 
selection. It reflects the initial testing done that identified the first 2 hit 
compounds all the way until the current PKZ 1800 analogs being tested in 
the second round of SAR studies.  
Liquid-Culture Screen: 
 Structural analogs PKZ 1821-1834 were tested in an initial screening at a concentration 
of 500µg/mL or 250 µg/mL, depending on solubility restraints. This initial testing was to 
determine which compounds demonstrate antimicrobial activity so that a full MIC assay could be 
conducted against both S. aureus and E. coli for the successful compound. To a 96-well plate we 
added 170 µL of media, 20 µL of media with inoculum, and 10 µL of 10 mg/mL compound for 
500 µg/mL final concentration or 5 µl of 10 mg/ml compound for 250 µg/mL final. Controls 
included a sterility control (TSB only), a positive growth control (TSB+bacteria), and DMSO 
control (5%DMSO+TSB+bacteria). Additionally, a titration of Gentamicin from 50 µg/mL to 0.1 
µg/mL was used to confirm there was no contamination by ensuring that the anticipated MIC of 
Gentamicin against the lab strain used was seen. Compound inhibition was determined 
quantitatively by measuring OD600 reading immediately after well inoculation and re-measuring 
following a 20 hour incubation period with plate shaking at 100 rpm at 37°C.  Inhibition was 
determined by the change in OD600 after the incubation period. If there is increase in optical 
density over the incubation period it demonstrates that bacterial growth is present.  
 
*The following information is proprietary and should be considered confidential. Please 
contact Dr. Paul Agris for permission prior to publishing. 
 
 
 
 
Results: 
Antibacterial testing of 15 Distinct Chemical Families: 
The first in silico yielded 200 compounds likely to disrupt T-box function and 28 of these 
compounds had been screened for activity. With 2 initial hits being pursued for SAR studies the 
search for potential more effective chemically distinct families continues. There 15 molecules of 
chemically distinct families screened during SAR studies. First disk diffusion assays were 
conducted at 150µg/mL against S. aureus to see if there was antibacterial activity.  Of these 2 
compounds there were 2 that showed potential inhibition, but the results were ambiguous.  To 
further ascertain there potential these compounds were screened at 300µg/mL, where they 
showed effectivity. These compounds were then tested in micro-dilution assays to determine 
the MIC and MBC concentrations. The results of these compounds screens are reflected by 
Table I. Both of these compounds, PKZ 0024 and PKZ 0034 showed no Gram-positive activity. 
PKZ 0034 demonstrated no activity against E.coli or S.aureus and PKZ 0024 showed activity 
against only E.coli at 481 µg/mL. 
 
 
 
 
 
 
 
 
         Table I: Distinct Chemical Families from AMRI Docking 
AMRI docking  
Top 200 molecules 
Zone of Inhibition (cm)  
Concentration 150µg/mL 
Zone of Inhibition (cm) 
Concentration 300µg/mL 
0021 NI NT 
0022 NI NT 
0023 NI NT 
0024 1.05 * 1.31* 
0025 NI NT 
0026 NI NT 
0027 NI NT 
0028 NI NT 
0029 NI NT 
0030 NI NT 
0031 NI NT 
0032 NI NT 
0033 NI NT 
0034 NI 0.956* 
0035 NI NT 
Compound S. aureus MIC (MBC) E. coli MIC (MBC) 
0024 N/O (N/O) 481 (N/O) 
0034 N/O (N/O) N/O (N/O) 
 
 
 
 
 
 
 
 
 
Table I: Legend 
NI= No Inhibition 
NT= Not Tested 
MIC = Minimum Inhibitory Concentration Assay 
MBC =Minimum Bactericidal Concentration Assay 
N/O= Not observed 
IND= Indeterminable 
*All concentrations above are in μg/mL 
SAR of Initial Hit Compounds PKZ 1800/PKZ 0600:  
Previous work has shown that initial hit compound PKZ 0600 demonstrated activity 
against various Gram-positive organisms and some Gram-negative organisms. All PKZ 0600 
analogs were screened using disk diffusion assays against S. aureus to determine if they had any 
activity. Those compounds with antimicrobial activity were selected for MIC and MBC assays. 
Table II shows the number of analogs tested and the number that showed activity in disk 
diffusion assays. PKZ 0600 had several components to its chemical structure, including a honey 
comb of three fused cyclic rings with an amide linkage followed by a carbon chain, leading to a 
piperzine moidy. This honey comb includes a fused benzene ring, pyrolidine ring, and partially 
unsaturated pyridine ring, which was substituted with an amide, alcohol, and carbonyl group. 
PKZ 0600 analogs varied in number and structure of fused rings with alternative structures cyclic 
and non-cylic in nature replacing the piperzine moidy.  
Compounds PKZ 0601, 0602, 0603, 0606, 0609, 0612, 0613 and 0615 all maintained an 
identical honey comb structure to PKZ 0600 including all three substituents attached to the 
pyrolidine ring. Variation between these analogs occurs in the alternate structures replacing the 
piperizine moidy. Analogs PKZ 0603, 0609, 0613 and 0615 showed antibacterial activity, but 
demonstrated no Gram-positive selectivity. Compounds PKZ 0603, 0609, and 0615 showed 
antibacterial activity against S. aureus in disk diffusion assays. Table III shows the results of 
MIC assays of these compounds against both S. aureus and E. coli. All three of these compounds 
demonstrated higher activity against the Gram-negative bacterium E. coli with MIC values of 
235µg/mL. These 3 compounds PKZ 0603 0609 and 0615 all had MIC values >235µg/mL 
against S. aureus demonstrating less activity against Gram-positive pathogens. 
Compounds PKZ 0604, 0605, and 0614 retained the honey comb structure of the parent 
compound, but contained an oxygen substituent instead of an alcohol on the partially unsaturated 
pyrolidine. Additionally, these compounds varied in there replacement of the piperizine moidy. 
Of these compounds only PKZ 0605 was effective and demonstrated minimal activity in disk 
diffusion assays, but it was not commercially available so no further testing was conducted. PKZ 
0600 analogs showed no specificity to Gram-positive bacteria in micro-dilution assays 
suggesting non-specific binding. As seen on Table I there was one exception to this, which was 
PKZ 0611. PKZ 0611 demonstrated high Gram-positive antimicrobial activity and no activity 
against the Gram-negative bacteria. This compound was unique containing 4 fused cyclic rings 
including, 2 piperidine rings with an oxygen substituent fused to pyran ring containing multiple 
oxygen substituents and an unsubstituted benzene ring. No obvious structural similarities were 
present between this PKZ 0600 analog and the effective PKZ 1800 analogs that showed Gram-
positive selectivity. There were 8 successful compounds amongst the PKZ 0600 analogs. Of 
these compounds, 5 contained a honey comb structure with two fused benzene rings and 
piperizine ring, but 6 unsuccessful compounds also had these chemical elements. There was no 
single element or combination of elements that were exclusively present in successful molecules 
making definitive conclusions difficult to draw.  
Prior testing conducted on initial hit PKZ 1800 showed Gram-positive selectivity. It was 
proven effective in both solid and liquid media culture screenings and was subject to testing with 
a variety of bacterial strains. Disk diffusion assays were conducted to ascertain analogs that had 
activity against S. aureus. This was done so that only those compounds with sufficient activity 
were tested in MIC and MBC assays. PKZ 1800 analogs revealed many significant findings and 
showed three chemical structures that were prominent in all of the compounds with the highest 
antibiotic activity. Disk diffusion assays were used to narrow in on compounds with activity 
levels of interest so that full MICs were only done on those compounds. Full MIC values were 
determined for compounds that showed activity in disk diffusion assays.  
There are 3 major components of the parent compound including a Norbornane 
carboxylic acid with an amide linkage in a meta orientation to the benzene ring substituent on the 
heterocyclic thiazole.  Additionally, there was a methyl group ortho to the benzene ring. Of the 
20 analogs of PKZ 1800 tested, 13 of these analogs contained the heterocyclic thiazole. All 
effective compounds retained this integral feature including compounds 1805, 1808, 1810, 1813, 
1819 and 1820. Compounds PKZ 1819 and PKZ 1820 contained the norbornane carboxylic acid, 
the heterocyclic thiazole, and the benzene ring identical to the parent compound. PKZ 1820 and 
PKZ 1819 showed inhibitory activity at concentrations of 117µg/mL and 481µg/mL respectfully, 
but had no activity against E. coli. These compounds differed from the parent compound in their 
substituents of the benzene ring. The parent compound has an isopropyl and the thiazole in a 
meta orientation on the benzene ring. PKZ 1819 has identical structure to the parent compound, 
but has two fluorine’s one ortho and one meta in orientation to the thiazole substituent on the 
benzene ring. PKZ 1820 has two chlorines one in ortho position and one in para position. Table 
III shows these results demonstrating compounds PKZ 1819 and 1820 have antibacterial activity 
and Gram-positive selectivity. PKZ 1813 contained both the norbornane carboxylic acid and the 
heterocyclic thiazole, but in replacement of the benzene ring the molecule had a thietane ring 
with no substituents. PKZ 1813 was effective in disk diffusion assays, but showed no activity in 
MIC assays against S. aureus or E. coli.  
Analogs PKZ 1805, 1808, and 1810 contained both the heterocyclic thiazole and the 
benzene ring with a cyclohexanoic acid with partial unsaturation in place of a norbornane 
carboxylic acid. The benzene ring substituents vary with these compounds with longer and 
shorter carbon chains instead of the isopropyl group present on the parent compound. PKZ 1805 
showed minimal success in disk diffusion assays and was not available commercially so no 
future testing was conducted with this molecule. As seen on Table III, compound PKZ 1808 
showed antibacterial activity at the 235µg/mL against S. aureus and 481 µg/mL against E. coli. 
PKZ 1808 had some Gram-positive selectivity. PKZ 1810 demonstrated antibacterial activity 
with no Gram-positive selectivity having MIC’s of 481µg/mL against both S. aureus and E. coli. 
Table II: 
Parent Compound Compounds Tested Compounds Successful 
PKZ 1800 20 6 
PKZ 0600 15 8 
  
 
 
 
 
 
 
 
 
 
 
 
Table II: Description 
This table demonstrates the amount of the structural analogs that 
showed activity against that showed activity at <300 µg/mL. Disk 
Diffusion assays were used to screen out compounds with activity of 
potential interest.  
 
Table III:  
Compound S. aureus MIC 
(MBC) 
E. coli MIC (MBC) 
1808 235 (N/O) 481 (N/O) 
1810 481 (N/O) 481 (N/O) 
1813 N/O (N/O) N/O (N/O) 
1819 481 (N/O) N/O(N/O) 
1820 117 (N/O) N/O(N/O) 
0603 481 (N/O) 235 (N/O) 
0607 481 (N/O) 235 (N/O) 
0609 N/O (N/O) 235 (N/O) 
0610 235 (481) 235 (481) 
0611 58.8 (N/O) N/O (N/O) 
0613 N/O (N/O) N/O (N/O) 
0614 N/O (N/O) N/O (N/O) 
0615 481 (N/O) 235 (481) 
 
 
 
 
 
 
Table III: Legend  
MIC = Minimum Inhibitory Concentration Assay 
MBC =Minimum Bactericidal Concentration Assay 
N/O= Not observed 
ND= Indeterminable 
 *All concentrations above are in μg/mL 
SAR round 2 of PKZ 1800:  
For the next round of SAR PKZ 1800 analogs became the main compound of focus. This 
was due to the fact that amongst the PKZ 0600 analogs there was no Gram-positive selectivity 
and structural determinations were ambiguous. Additionally, cytotoxicity data conducted by the 
Wadsworth center demonstrated that the PKZ 0600 parent compound had far higher cytotoxicity 
to mammalian cells then PKZ 1800. With all of these factors considered, efforts were invested in 
compounds similar in structure to parent compound PKZ 1800. PKZ 1800 analogs displaying 
antibacterial activity and Gram-positive selectivity in SAR round 1 were used as a structural 
template for future compounds of testing. Compounds were chosen based on the presence of 
specific combinations of structures that might further enhance antimicrobial activity or provide 
valuable information about the importance of certain structures. This included compounds both 
containing and lacking the benzene ring, methyl group, isopropyl group or norbornane 
carboxylic acid. All molecules contained the heterocyclic thiazole. Unique molecules with new 
structural elements replacing the norbornane carxboxylic acid were tested in search of a possibly 
better replacement for the norbornane structure.  
The 22 potential molecules selected were put into an in silico analysis to ascertain 
whether these new compounds were likely to bind the Specifier Loop. Top candidates of this 
docking simulation as well as other carefully selected analogs were tested at 500 µg/mL to 
determine if they were compounds of interest. Using solubility for guidelines, all compounds that 
were not soluble enough to determine an accurate determination of growth were used at lower 
testable concentrations. This included concentrations that would have an initial OD600 less than 
0.7. Table IV shows the results from this initial screen, which yielded 5 compounds with 100% 
inhibition at 500 µg/mL. The results of these experiments can be seen on Table IV.  
As seen on Table IV, Analogs PKZ 1821, 1822, 1823, 1825 and 1833 showed 100% 
inhibition at 500 µg/mL. PKZ 1821, 1822, 1823, 1825, and 1833 have been tested with full MIC 
and MBC assays against S. aureus and E. coli (Table V). Analog PKZ 1821 was identical to the 
parent compound with the exception of the removal of a single methyl group bound to the 
heterocyclic thiazole ortho in relation to the benzene ring. PKZ 1821 demonstrated a MIC of 
58µg/mL against S. aureus and no MIC against E. coli. PKZ 1822’s structure includes the 
removal of the methyl group and the addition of a carbon to the isopropyl group bound to the 
benzene ring making it an isobutyl group. As reflected in Table V, PKZ 1822 had the highest 
antibacterial activity and Gram-positive selectivity of any compound tested with a MIC of 29 
µg/mL against S. aureus and no MIC against E. coli.  
Chemical compound PKZ 1823 lacked the methyl group on the heterocyclic thiazole, and 
contained 2 methyl groups on the benzene ring instead of the isopropyl group. This compound 
only showed activity at 250 µg/mL in initial screen (Table IV), but did not show any activity in 
the full MIC assay testing at < 235 µg/mL (Table V). PKZ 1825 maintains the exact same 
structure as the parent compound, but removes the entire isopropyl group from the benzene ring. 
Additionally, PKZ 1825 lacks the carboxylic acid. As seen on Table III, PKZ 1825 showed 
activity at 235µg/mL against both S. aureus and E. coli suggesting that the carboxlic acid on the 
Norbornane is essential for Gram-positive selectivity. The higher activity of PKZ 1821 and PKZ 
1822 may suggest the importance of the carboxylic acid present on the norbornane. It also 
supports that the methyl substituent on the thiazole rings is not necessary for optimal activity. 
Lastly, PKZ 1833 was a unique compound containing an alternative structure to the norbornane. 
In addition, this compound lacks the methyl group on the heterocyclic thiazole and has an amide 
in replacement of the benzene ring. This is the only compound that demonstrated activity without 
the benzene ring. This compound was tested at 500 µg/mL and showed activity (Table IV), but 
showed no activity at < 235 µg/mL in the full MIC assay (Table V).   
  Table IV:  
Concentration 
(µg/mL) 
Compound %Inhibition Solubility 
500 1821 100* NCS 
1822 100* NCS 
1823 100* NCS 
1824 47 S 
1825 100* NCS 
1826 53* NCS 
1827 46 S 
1828 57 S 
1829 44 S 
1830 36 NCS 
1831 0 S 
1832 31 NCS 
1833 100 NCS 
1834 0 NCS 
250 1821 100 NCS 
1822 100 NCS 
1823 100 NCS 
1825 100 NCS 
1826 47 NCS 
 
 
 
 
  
 
 
 
 
 
Table IV: Legend   
NCS = Not completely soluble  
S = Soluble  
*  = Background OD above 0.7 
              Table V: 
Compound S. aureus MIC (MBC) E. coli MIC (MBC) 
PKZ 1821 58.8 (N/O) N/O (N/O) 
PKZ 1822 29.4 (IND) N/O (N/O) 
PKZ 1823 250 (N/O) N/O (N/O) 
PKZ 1825 235 (N/O) 235 (N/O) 
PKZ 1833 N/O (N/O)  N/O (N/O) 
  
 
 
 
 
 
 
Discussion: 
Thorough evaluation of the chemical structures of the first round SAR compounds 
suggests that the heterocyclic thiazole is an essential component for antibacterial activity 
amongst PKZ 1800 analogs. All successful PKZ 1800 analogs contained this integral structural 
feature. Due to the fact that some compounds that were not effective contained the heterocyclic 
thiazole, this suggests that the structure is necessary, but may not be sufficient for optimal 
activity. The presence of a benzene ring seems to act synergistically with the thiazole ring as all 
Table V: Legend 
   MIC = Minimum Inhibitory Concentration Assay 
 MBC =Minimum Bactericidal Concentration Assay 
 N/O= Not observed MIC at concentrations <235 µg/mL 
 IND= Indeterminable 
 *All concentrations above are in μg/mL 
compounds that depicted significant antimicrobial activity in micro-dilution assays contained the 
two connected aromatic structures. Interestingly, neither of these components would ensure the 
desired Gram-positive specificity from these antimicrobial agents. Further evaluation of PKZ 
1800 analogs revealed that all compounds containing the norbornane carboxylic acid structure 
showed specificity towards inhibition of the Gram-positive organisms. PKZ 1800 analogs, PKZ 
1808 and PKZ 1810 lacked the selectivity that was seen in PKZ 1819 and 1820. The major 
distinguishing chemical element between these pairs of analogs was the presence of a 
norbornane carboxylic acid. PKZ 0600 analogs demonstrated no commonalities amongst 
successful compounds making structural assertions very difficult. Based on the Gram-positive 
selectivity, increased antimicrobial activity, and cytotoxicity, PKZ 1800 analogs became the 
main focus of second round SAR studies.  
Our structure-activity relationship studies reflected the integral nature of the heterocyclic 
thiazole present in PKZ 1800. It was present in all effective PKZ 1800 analogs.  Thiazoles have 
pharmaceutical significance and have been shown to have a variety of biological functions. They 
have led to a variety of antifungals, antioxidants, antibacterial, antitubercular, antidiuretic, anti-
inflammatory and anticancer activities.
20
 
Currently used thiazole antibiotics have been shown to act on bacterial RNA targets. A 
study conducted by Lentzen et al
21
 showed that thiazole antibiotics thiostrepton, micrococcin, 
siomycin, and nosiheptide have a 100 fold higher selectivity for inhibition of bacterial translation 
over eukaryotic. Results from this study suggest that thiazole antibiotics nosiheptide, 
thiostrepton, and siomycin had a high affinity for the L11 binding domain (L11BD) of 23S 
ribosomal RNA and interact to alter its confirmation. 3D modeling revealed stacking interactions 
between all four antibiotic thiazole moieties and the quinaldic acid (QA) residue of the rRNA.
21 
The benzene ring appears to be a significant component as all compounds with 
antibacterial activity in second round SAR had this structure. Several compounds tested in the 
liquid culture screen assay were almost identical to parent compound PKZ 1800, except without 
a present benzene ring and yet these compounds showed no activity. Pi stacking is a potential 
mechanism of interaction between a benzene ring and RNA target. Variation in effective 
structures may be a result of the diversity of substituents of this element. A recent computation 
study by Marcey L Waters
22
 discusses the strong interactions that can occur between biological 
elements and aromatic rings as a result of their hydrophobic nature. This includes interactions 
with water where a quadrupole moment may form resulting in an increase in electron density 
towards the face the aromatic ring making it more reactive with negatively charged RNA.
22
 A 
study by Cammers-Goodwin et al
23
 suggested that water can act with the hydrogens of aromatic 
rings to facilitate pi stacking.
23
 Under normal conditions the large presence of water in a cell may 
facilitate this type of interaction between a small putative antibiotic and Specifier Loop of the T-
box element. Both aromatic rings including the heterocyclic thiazole and the benzene ring appear 
essential for significant activity. Their importance may be because of a hydrophobic stacking 
mechanism that promotes interaction between these aromatic rings and the Specifier Loop of a 
nascent mRNA.   
Antibacterial activity of aromatic rings can be altered drastically by the position and 
identity of functional groups substituents. In an antimycobacterial study conducted by Makam et 
alREF against M. tuberculosis thiazole compounds linked to benzene rings through amines were 
tested and the effectivity of varying substituents and positions were evaluated.  In one case, the 
presence of an alcohol attached at 2nd, 3rd and 4th positions of the benzene ring resulted in 
significant differences in bacterial activity. At the 3rd and 4th position a MIC >200 µM was 
seen, but at the 2nd position activity significantly increased, resulting in a MIC of 25 µM.
24
  
Our results are reflective of this as there as changes in activity were observed depending 
on the substituents present on the aromatic rings. PKZ 1822 was the most effective compound in 
SAR studies. It differed from PKZ 1800 by removal of a methyl group on the heterocyclic 
thiazole and presence of an isobutyl group instead of an isopropyl group on the benzene ring. 
These alterations may be significant as lengthening the carbon chain on the benzene ring 
increases surface area and van der waals forces, which may allow for more efficient binding to 
the Specifier Loop. PKZ 1821 had increased activity from past analogs and also lacked the 
methyl group on the heterocyclic thiazole. PKZ 1825 demonstrated the least activity and Gram-
positive selectivity of the three compounds, and still contained the methyl group on the thiazole. 
This evidence supports that the methyl group has no contribution to bacterial inhibition and 
possibly hinders it. Once main structural elements are revised, a future direction for 
consideration would be to conduct thorough evaluation of the effectiveness of various 
substituents at different positions on the aromatic rings to further optimize activity. 
Determining structural components important for antibacterial activity allows for a faster 
and more efficient approach to drug discovery, which has been aided by modern technology. 
Resistance is on the rise and the process to discover new and novel antibiotics is extensive and 
costly. Utilizing sophisticated computer software is an essential tool in expediting the process to 
creating new antibiotics.
25
 Ultimately, as stated in the CDC threat report the resistance process 
can only be “slowed” not stopped.
11
 Computer-aided drug design (CADD) provides bio-chemical 
prediction models such as, in silico, which conducts large scale predictions on chemical 
molecules binding energies, poor activity, poor absorption, distribution, metabolism, excretion, 
and toxicity preventing wasted time and resources. Newer developments in these technologies 
have allowed for efficient discovery with expedited refining of physicochemical and 
ADMET/PK (pharmacokinetic) properties.
25 
With new and efficient models to test molecules there is great need for novel targets. 
RNA has a diverse and integral function to transcription regulation, gene expression, and 
translation of protein. The diversity and specificity of RNA coupled with its lack of the extensive 
repair mechanisms of DNA make it an ideal target for drug discovery. Prior RNA drug targeting 
has been directed towards rRNA with drug classes such as aminoglycosides. mRNA and 
riboswitch regulator elements on  nascent transcripts are novel drug targets for a variety of 
reasons. These regulatory elements monitor essential processes for bacterial survival and remain 
very distinct from eukaryotic mRNA.
26
  
The combination of rising resistance, decrease in antibiotic innovation, strict US Food 
and Drug Administration (FDA) regulation, and lack of economic incentive for pharma 
companies, demonstrates the need for efficient methods to drug discovery. RNA targets such as 
riboswitches are ideal drug targets because their integral nature in bacterial survival decreases 
possibility of resistance and their elucidated structure allows for efficient computerized 
approach.
27 
Using in silico screening and bacterial susceptibility to narrow integral structural 
elements allows for the expedited discovery of new novel antibiotic classes, which are 
desperately in demand. 
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